ArticleWorld journal of surgical oncology2026
Analysis of ovarian cancer burden among reproductive-aged women and its association with the socio-demographic index from 1990 to 2021.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study analyzed the global burden of ovarian cancer in reproductive-aged women (1990–2021) to identify trends, drivers, and project future trends for guiding prevention strategies.
methodsUsing Global Burden of Disease 2021 data, we analyzed ovarian cancer burden and its association with the Socio-demographic Index (SDI). Trends were evaluated using average annual percentage change and Age-Period-Cohort modeling, with projections to 2036 via ARIMA models.
resultsIn 2021, there were 85,749 new cases and 25,258 deaths globally among reproductive-aged women. The age-standardized rates declined from 1990 to 2021. Projections indicate stable age-standardized incidence and prevalence rates through 2036, but further declines in mortality and DALY rates. Significant regional disparities persist, with the burden decreasing in high-SDI regions but increasing in low- and middle-SDI regions. Disease risk increased after age 35. Successive birth cohorts from the 1990s onward showed a higher baseline risk. Population growth was the primary driver of increasing case numbers. High body mass index (BMI) was the leading risk factor.
conclusionsWhile the global burden of ovarian cancer is declining, substantial regional heterogeneity exists. Tailored strategies focusing on high-risk populations and modifiable factors like high BMI are crucial to mitigate the disease's impact and reduce disparities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.